Click play icon ▶️ to listen (transcript follows below): As a sought-after medical imaging industry thought leader, Mike Harsh sat for a recorded interview by
Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead nanoparticle
Appendix 4C, “December 2018 Quarterly Update” was lodged with the Australian Securities Exchange on 31st January. View the Appendix 4C.
Form 603, “Notice of initial substantial holder” was lodged with the Australian Securities Exchange on 30th January at 5:29 PM. View the form 603.
Form 603, “Notice of initial substantial holder” was lodged with the Australian Securities Exchange on 30th January at 5:25 PM. View the Form 603.
MELBOURNE, Australia, Dec. 17, 2018 /PRNewswire/ — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet
Imagion Biosystems Limited (ASX: IBX) has lodged “Notice Pursuant to Section 708A(5)(e) of the Corporations Act” with the Australian Securities Exchange. View Notice Pursuant to Section
Imagion Biosystems Limited (ASX: IBX) has lodged “Appendix 3B: New issue announcement, application for quotation of additional securities and agreement” with the Australian Securities Exchange.
Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company’s early cancer detection technology, its place in the the
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance